BRIEF-Innoviva Specialty Therapeutics Signs Exclusive Distribution And Licensing Agreement To Acquire U.S. Marketing Rights For Zevtera®

Reuters2024-12-16

Dec 16 (Reuters) - Innoviva Inc :

* INNOVIVA SPECIALTY THERAPEUTICS SIGNS EXCLUSIVE DISTRIBUTION AND LICENSING AGREEMENT TO ACQUIRE U.S. MARKETING RIGHTS FOR ZEVTERA® (CEFTOBIPROLE)

* INNOVIVA INC: UNDER TERMS OF AGREEMENT, INNOVIVA, INC., WILL BE GRANTED EXCLUSIVE MARKETING RIGHTS TO ZEVTERA IN U.S.

* INNOVIVA INC: UNDER AGREEMENT TERMS, BASILEA WILL RECEIVE $4 MILLION UPFRONT PAYMENT IN ADDITION TO TIERED ROYALTIES AND MILESTONES ON NET SALES IN U.S.

* INNOVIVA INC: INNOVIVA SPECIALTY THERAPEUTICS ANTICIPATES COMMERCIALIZING ZEVTERA IN MID-YEAR 2025

Source text: Further company coverage:

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2491466070?lang=en_US&edition=full_marsco","thumbnail":"","is_english":true,"pubTime":"2024-12-16 20:37","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2491466070","market":"us","top_or_hot":-1,"title":"BRIEF-Innoviva Specialty Therapeutics Signs Exclusive Distribution And Licensing Agreement To Acquire U.S. Marketing Rights For Zevtera®","media":"Reuters","content":"<html><body><p>Dec 16 (Reuters) - Innoviva Inc   :</p><p>   * INNOVIVA SPECIALTY THERAPEUTICS SIGNS EXCLUSIVE DISTRIBUTION AND LICENSING AGREEMENT TO ACQUIRE U.S. MARKETING RIGHTS FOR ZEVTERA® (CEFTOBIPROLE)</p><p>   * INNOVIVA INC: UNDER TERMS OF AGREEMENT, INNOVIVA, INC., WILL BE GRANTED EXCLUSIVE MARKETING RIGHTS TO ZEVTERA IN U.S.</p><p>   * INNOVIVA INC: UNDER AGREEMENT TERMS, BASILEA WILL RECEIVE $4 MILLION UPFRONT PAYMENT IN ADDITION TO TIERED ROYALTIES AND MILESTONES ON NET SALES IN U.S.</p><p>   * INNOVIVA INC: INNOVIVA SPECIALTY THERAPEUTICS ANTICIPATES COMMERCIALIZING ZEVTERA IN MID-YEAR 2025</p><p>Source text:    Further company coverage:   </p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Innoviva Specialty Therapeutics Signs Exclusive Distribution And Licensing Agreement To Acquire U.S. Marketing Rights For Zevtera®</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Innoviva Specialty Therapeutics Signs Exclusive Distribution And Licensing Agreement To Acquire U.S. Marketing Rights For Zevtera®\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2024-12-16 20:37</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p>Dec 16 (Reuters) - Innoviva Inc   :</p><p>   * INNOVIVA SPECIALTY THERAPEUTICS SIGNS EXCLUSIVE DISTRIBUTION AND LICENSING AGREEMENT TO ACQUIRE U.S. MARKETING RIGHTS FOR ZEVTERA® (CEFTOBIPROLE)</p><p>   * INNOVIVA INC: UNDER TERMS OF AGREEMENT, INNOVIVA, INC., WILL BE GRANTED EXCLUSIVE MARKETING RIGHTS TO ZEVTERA IN U.S.</p><p>   * INNOVIVA INC: UNDER AGREEMENT TERMS, BASILEA WILL RECEIVE $4 MILLION UPFRONT PAYMENT IN ADDITION TO TIERED ROYALTIES AND MILESTONES ON NET SALES IN U.S.</p><p>   * INNOVIVA INC: INNOVIVA SPECIALTY THERAPEUTICS ANTICIPATES COMMERCIALIZING ZEVTERA IN MID-YEAR 2025</p><p>Source text:    Further company coverage:   </p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"INVA","symbol_name":"Innoviva, Inc.","start_time":0,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","article_id":"2491466070","we_media_id":"1036604489","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2491466070","pubTimestamp":1734352629,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"summary":"Dec 16  - Innoviva Inc   :   * INNOVIVA SPECIALTY THERAPEUTICS SIGNS EXCLUSIVE DISTRIBUTION AND LICENSING AGREEMENT TO ACQUIRE U.S. MARKETING RIGHTS FOR ZEVTERA    * INNOVIVA INC: UNDER TERMS OF AGREEMENT, INNOVIVA, INC., WILL BE GRANTED EXCLUSIVE MARKETING RIGHTS TO ZEVTERA IN U.S.   * INNOVIVA INC: UNDER AGREEMENT TERMS, BASILEA WILL RECEIVE $4 MILLION UPFRONT PAYMENT IN ADDITION TO TIERED ROYALTIES AND MILESTONES ON NET SALES IN U.S.   * INNOVIVA INC: INNOVIVA SPECIALTY THERAPEUTICS ANTICIPATES COMMERCIALIZING ZEVTERA IN MID-YEAR 2025Source text:    Further company coverage:","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"INVA":"Innoviva, Inc.","BK4007":"制药","LENZ":"Therapeutics","BK4139":"生物科技"},"translate_title":"简介-Innoviva Specialty Therapeutics签署独家分销和许可协议，获得Zevtera®在美国的营销权","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"INVA":1,"LENZ":1},"content_text":"Dec 16 (Reuters) - Innoviva Inc   :   * INNOVIVA SPECIALTY THERAPEUTICS SIGNS EXCLUSIVE DISTRIBUTION AND LICENSING AGREEMENT TO ACQUIRE U.S. MARKETING RIGHTS FOR ZEVTERA® (CEFTOBIPROLE)   * INNOVIVA INC: UNDER TERMS OF AGREEMENT, INNOVIVA, INC., WILL BE GRANTED EXCLUSIVE MARKETING RIGHTS TO ZEVTERA IN U.S.   * INNOVIVA INC: UNDER AGREEMENT TERMS, BASILEA WILL RECEIVE $4 MILLION UPFRONT PAYMENT IN ADDITION TO TIERED ROYALTIES AND MILESTONES ON NET SALES IN U.S.   * INNOVIVA INC: INNOVIVA SPECIALTY THERAPEUTICS ANTICIPATES COMMERCIALIZING ZEVTERA IN MID-YEAR 2025Source text:    Further company coverage:","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.32.1","shortVersion":"4.32.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2491466070"}